$TELO News

Last published 1mo ago

1mo agoTELOTelomir Announces Peer-Reviewed Publication Showing Telomir-Zn Restores Visual Function and Retinal Structure in a Model of Age-Related Macular Degeneration (AMD)GlobeNewswireMIAMI, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of
2mo agoTELOTelomir Announces Research with The Ohio State University Demonstrating In-Vitro Anti-Cancer Activity in Human and Canine Osteosarcoma ModelsGlobeNewswireMIAMI, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of
3mo agoTELOTelomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer ModelsGlobeNewswireMIAMI, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer,
5mo agoTELOTelomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes ModelACCESS NewswireInsulin Resistance Was Normalized Following 14 Days of Treatment, Supporting Restoration of Glucose Metabolism and Insulin Sensitivity and Further Validating Telomir-Zn's Metal-Homeostasis Mechanism Across Multiple
5mo agoTELOTelomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's DiseaseACCESS NewswireStudy Published in Advances in Redox Research Demonstrated Dose-Dependent Survival Improvement, Reduced Hepatic Copper Burden, Improved Liver Biomarkers, and Reduced Tissue Degeneration in a Preclinical Wilson's Disease
6mo agoTELOTelomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast CancerACCESS NewswireCompany Plans to Initiate First-in-Human Phase 1/2 Trial in 1H 2026, Anchored by a Leading U.S. Academic Medical Center. MIAMI, FL / ACCESS Newswire / April 30, 2026 / Telomir Pharmaceuticals, Inc.
6mo agoTELOTelomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn)ACCESS NewswireTransaction establishes global ownership rights of lead program and includes initial capital funding with additional optional milestone-based capital support aligned with key clinical milestones. MIAMI, FL / ACCESS
7mo agoTELOTelomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) in Advanced and Metastatic Triple-Negative Breast CancerACCESS NewswireFirst-in-class metal-modulating epigenetic therapy targeting iron-dependent pathways with preclinical efficacy and a favorable GLP safety profile.MIAMI, FL / ACCESS Newswire / March 31, 2026 / Telomir Pharmaceuticals,
8mo agoTELOTelomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer ModelsACCESS NewswireIron-rescue experiments confirm tumor cell mortality is mechanistically driven, not nonspecific cytotoxicity.MIAMI, FL / ACCESS Newswire / February 17, 2026 / Telomir Pharmaceuticals, Inc. ("Telomir" or the
9mo agoTELOTelomir Pharmaceuticals Reports New Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and AgingACCESS NewswireCellular findings show Telomir-Zn modulates intracellular metal balance linked to oxidative stress, mitochondrial dysfunction, DNA methylation instability, and genomic integrity-without relying on cytotoxic
11mo agoTELOTelomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical DevelopmentACCESS NewswireNo treatment-related adverse toxicity was observed across completed GLP studies, with consistent systemic exposure following oral administration.MIAMI, FL / ACCESS Newswire / December 18, 2025 / Telomir Pharmaceuticals,
11mo agoTELOTelomir Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in Human Prostate Cancer CellsACCESS NewswirePSA is a validated FDA-recognized clinical endpoint in assessing prostate cancer treatment response; Telomir-1 lowered PSA levels in a dose-related manner. MIAMI, FLORIDA / ACCESS Newswire / November 25, 2025 / Telomir
11mo agoTELOTelomir Pharmaceuticals Announces Telomir-1 Kills Aggressive Human Leukemia CellsACCESS NewswireFindings expand Telomir-1's oncology profile into cancers of the blood, adding to previously reported activity in triple-negative breast, pancreatic, and aggressive prostate cancer models. MIAMI, FL / ACCESS Newswire /
1y agoTELOTelomir Pharmaceuticals Reports Telomir-1 Outperforms FDA-Approved Gold-Standard Iron Chelator Deferoxamine (DFO) in Reducing Intracellular Iron in a Human Cell LineACCESS NewswireNew live-cell imaging data show that Telomir-1 markedly lowers intracellular iron levels at submicromolar concentrations in human keratinocytes, demonstrating potent cell penetration and iron-modulating activity - key to
1y agoTELOTelomir Pharmaceuticals Reports New Data Showing Telomir-1 Resets Cancer's "Kill-and-Clean" Defense Systems in an Aggressive Prostate Cancer Model, Outperforming Rapamycin and ChemoACCESS NewswireNew findings highlight Telomir-1's impact on CASP8 and GSTP1, two critical genes that regulate cell death and glutathione-based detoxification pathways often disrupted in cancer. MIAMI, FLORIDA / ACCESS Newswire /
1y agoTELOTelomir Pharmaceuticals Executes Binding LOI for Worldwide Rights to Telomir-1, Positioning the Company for Global Market Expansion and Value GrowthACCESS NewswireUnifying global IP rights and enabling up to $5 million in potential shareholder contributions, the agreement strengthens Telomir's foundation for partnerships, licensing, and long-term value creation. MIAMI, FLORIDA /
1y agoTELOTelomir Pharmaceuticals Announces New Data Showing That Telomir-1 Kills Aggressive Pancreatic Cancer Cells, One of the Deadliest Forms of CancerACCESS NewswireFindings complement previously announced results in triple-negative breast cancer and prostate cancer models, highlighting Telomir-1's consistent impact on cancer cell survival pathways. MIAMI, FLORIDA / ACCESS
1y agoTELOTelomir Pharmaceuticals Reports Discovery That Telomir-1 Selectively Kills Aggressive Triple-Negative Breast Cancer CellsACCESS NewswireNew findings show Telomir-1 shuts down cellular energy pathways and mitochondrial function in aggressive breast cancer cells, leading to cell death through iron-dependent regulation. MIAMI, FL, 2654 / ACCESS Newswire /
1y agoTELOTelomir Pharmaceuticals Announces New Findings in a Prostate Cancer Model Demonstrating Telomir-1 Also Resets DNA Methylation of Tumor Suppressor Genes Implicated in Two of the Most Persistent Challenges in Oncology-Metastasis and Treatment ResistanceACCESS NewswireFindings show that Telomir-1 restores the body's natural tumor suppressor defenses by reversing abnormal DNA methylation of MASPIN and RASSF1A - genes that help block invasion, limit metastasis, and improve chemotherapy
1y agoTELOTelomir Pharmaceuticals Announces New Cancer Data in Aggressive Human Prostate Cancer Cells Showing Telomir-1 Resets DNA Methylation to Reactivate CDKN2A, a Master Tumor Suppressor, Outperforming Rapamycin and ChemotherapyACCESS NewswireNew preclinical findings highlight Telomir-1's ability to reverse CDKN2A gene silencing by DNA methylation, reactivating this gene - often called the body's natural "cell cycle brake." These results build on
1y agoTELOTelomir Pharmaceuticals Reports In Vitro Data Supporting the Potential of Telomir-1 as a First-in-Class Epigenetic Therapy Influencing DNA Methylation Pathways in Cancer, Aging, and Age-Related DiseasesACCESS NewswireIn vitro findings reveal Telomir-1's dual action: targeting DNA methylation switches and cutting into the Wnt "fuel line" that drives cancer growth. MIAMI, FLORIDA / ACCESS Newswire / August 28, 2025 / Telomir
1y agoTELOTelomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Inhibits Key Epigenetic Enzymes Driving Tumor Growth, Autoimmune Disease, Neurodegeneration, and Metabolic DysfunctionACCESS NewswireNew data from Eurofins Discovery show that Telomir-1 blocks enzymes that drive disease by turning off critical genes-highlighting its potential to treat cancer, autoimmune conditions, neurodegeneration, and metabolic
1y agoTELOTelomir Pharmaceuticals Reports Telomir-1's Unique Profile Restores Mitochondrial Health While Improving Oxidative Stress Without Promoting Cell Proliferation in Diseased Human Cell Lines Highlighting Potential Relevance to Neurodegenerative Pathways in Alzheimer's and Parkinson'sACCESS NewswireThis unique cellular activity may help restore energy balance and improve essential cell functions such as protein synthesis and membrane stability in diseases like Parkinson's ALS Alzheimer's and Progeria where
1y agoTELOTelomir Demonstrates Telomir-1 Reverses Epigenetic Gene Silencing of STAT1, Restoring Tumor Suppressor in Human Prostate Cancer Cells, Outperforming Chemotherapy and RapamycinACCESS NewswireNew data shows Telomir-1 fully reverses STAT1 gene silencing by DNA methylation - a key immune regulator suppressed in cancer - delivering stronger epigenetic effects than Paclitaxel or Rapamycin in aggressive PC3 tumor
1y agoTELOTelomir Pharmaceuticals Prevents Cellular Aging in Patient-Derived Cells from Children with Progeria - an Ultra-Rare Genetic Disorder that Causes Rapid AgingACCESS NewswireStudy used cell lines obtained from the Progeria Research Foundation to evaluate Telomir-1's effects on key drivers of accelerated aging MIAMI, FLORIDA / ACCESS Newswire / June 18, 2025 / Telomir Pharmaceuticals, Inc.
1y agoTELOTelomir Pharmaceuticals Announces Telomir-1 Demonstrates Dose-Dependent Restoration of Neurological, Liver and Kidney Functions in Preclinical Wilson's Disease ModelACCESS NewswireTreatment reversed tremors, ataxia, anxiety-like behavior, liver and kidney pathology damage, reduced copper accumulation, normalized ALT, AST, and bilirubin levels, and improved survival.Building on previous data in
1y agoTELOTelomir Pharmaceuticals Announces Telomir-1 Resets the Body's Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated Aging Animal Model of Werner SyndromeACCESS NewswireTreatment restored gene control, extended telomere length beyond healthy levels, reversed muscle and weight loss, reduced oxidative stress, and resulted in 100% survival - highlighting Telomir-1's potential to reverse
1y agoTELOTelomir Pharmaceuticals to Participate in BIO 2025 in Boston as Company Prepares for IND Submission and Advances Breakthrough Longevity PlatformACCESS NewswireCompany to meet with prospective partners as it accelerates toward IND submission for Telomir-1, with plans to begin human dosing in the first half of 2026 MIAMI, FL / ACCESS Newswire / June 2, 2025 / Telomir
1y agoTELOTelomir Pharmaceuticals Confirms Telomir-1 Restores Vision and Retinal Structure in Age-Related Macular Degeneration (AMD) Animal Model Using FDA-Recognized Surrogate EndpointsACCESS NewswireA unique oral drug candidate that is shown to restore vision and regenerate the retina in an animal model, addressing a major unmet need in ocular therapeutics MIAMI, FLORIDA / ACCESS Newswire / May 29, 2025 / Telomir
1y agoTELOTelomir Pharmaceuticals Secures $3 Million at a Premium in Straight Equity Sale Involving No Warrants to Advance Rare Disease INDACCESS NewswireInvestment from largest shareholder strengthens balance sheet, signals insider conviction, and funds Telomir-1's upcoming IND submission for a rare disease indication MIAMI, FLORIDA / ACCESS Newswire / May 21, 2025 /
1y agoTELOTelomir Pharmaceuticals Adds Telomir-Ag2 as a Novel Drug Candidate to Pipeline Following Breakthrough Efficacy Against MARSA and Drug-Resistant Infections, Targeting a $30B+ Antimicrobial Market OpportunityACCESS NewswireAntimicrobial resistance is recognized as one of the top global public health threats, and Telomir-Ag2 strengthens Telomir's pipeline with a differentiated candidate designed to address this urgent and expanding crisis
1y agoTELOTelomir Pharmaceuticals Demonstrates Telomir-1 Reverses Key Drivers of Cellular Decline in Human Cell Lines Supporting Therapeutic Potential in Autism and Spasmodic DysphoniaACCESS NewswireMIAMI, FLORIDA / ACCESS Newswire / May 7, 2025 / Telomir Pharmaceuticals, Inc. , a leader in age-reversal science, today announced new preclinical data showing that its lead oral drug
1y agoTELOTelomir Pharmaceuticals Announces Significant Anti-Cancer Effects in Prostate Cancer Animal Model Using Highly Aggressive Human Prostate Cancer CellsACCESS NewswireTelomir-1 Inhibits Tumor Growth, Suppresses Cancer Progression, and Neutralizes Chemotherapy Toxicity MIAMI, FLORIDA / ACCESS Newswire / March 19, 2025 / Telomir Pharmaceuticals, Inc. ,
1y agoTELOTelomir Pharmaceuticals Announces Breakthrough: Telomir-1 Reverses Calcium Dysregulation, the Hidden Driver of Aging and Disease, in Multiple Human Cell LinesACCESS NewswireNew Study Confirms Telomir-1 Also Reverses Oxidative Stress, Preserves Cellular Integrity, and Prevents Cell Death by Protecting Mitochondria-The Cell's Power Source and Gatekeeper of Life and Death MIAMI, FLORIDA /
1y agoTELOTelomir Pharmaceuticals Achieves Breakthrough in Silver Ion Stabilization, Unlocking a Multi-Billion-Dollar Medical MarketACCESS NewswireMIAMI, FLORIDA / ACCESS Newswire / February 21, 2025 / Telomir Pharmaceuticals, Inc. , or Telomir, a leader in age-reversal science, today announced a breakthrough achievement-Telomir-1 has successfully
1y agoTELOTelomir Pharmaceuticals Announces Significant Reduction of Oxidative Stress in Human Retinal Cell Lines, Advancing Potential Treatment for Age-Related Macular Degeneration (AMD)ACCESS NewswireMIAMI, FLORIDA / ACCESS Newswire / February 18, 2025 / Telomir Pharmaceuticals, Inc. , or Telomir, a leader in age-reversal science, today announced groundbreaking results from its recent preclinical studies
1y agoTELOTelomir Pharmaceuticals Announces Breakthrough Results With Telomir-1 Fully Reversing Oxidative Stress in Human Cell Lines and Exploring Potential as a Treatment for Avian Influenza (Bird Flu) and Other VirusesACCESS NewswireOxidative stress drives aging and is a key factor in diseases like Alzheimer's, Age-related Macular Degeneration , cardiovascular diseases, cancer, and diabetes. It also plays a critical role in the progression of
1y agoTELOTelomir Pharmaceuticals Confirms Lifespan Restoration and Normalization of Accelerated Aging in Preclinical Model of Progeria (A Rare Genetic Disorder Causing Rapid Aging)ACCESS NewswireMIAMI, FL / ACCESSWIRE / January 7, 2025 / Telomir Pharmaceuticals, Inc. , an emerging leader in age-reversal science focused on treating the root causes of diseases rather than just
1y agoTELOTelomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson's DiseaseACCESS NewswireMIAMI, FL / ACCESSWIRE / December 23, 2024 / Telomir Pharmaceuticals, Inc. , or the "Company", an emerging leader in age-reversal science, today announced significant findings from its copper
1y agoTELOTelomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing PriceACCESS NewswireTransaction follows a $5 million non-dilutive credit line from the same trusted partner, further reinforcing Telomir's financial strength and growth potential. MIAMI, FL / ACCESSWIRE / December 12, 2024 / Telomir
1y agoTELOTelomir Pharmaceuticals Announces Reversal of Key Type 2 Diabetes Parameters in Groundbreaking Preclinical Study With Telomir-1ACCESS NewswireBuilding on preclinical success demonstrating age reversal, longevity, and increased healthspan, Telomir-1 appears to address insulin resistance at its root, achieving reversal to near pre-diabetic levels MIAMI, FL /
1y agoTELOTelomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1ACCESS NewswireMIAMI, FL / ACCESSWIRE / November 21, 2024 / Telomir Pharmaceuticals, Inc. , an emerging leader in age-reversal science, today announced groundbreaking
2y agoTELOTelomir Pharmaceuticals Special Advisor Dr. Michael Roizen to Discuss Telomir-1 and the Science of Longevity on Health Uncensored With Dr. Drew on the Fox Business Network This SundayACCESS NewswireInterview to Air Sunday, September 29, 2024 at 5:30 PM EST on Fox Business NetworkMIAMI, FL / ACCESSWIRE / September 26, 2024 / Telomir Pharmaceuticals , a
2y agoTELOTelomir Pharmaceuticals Appoints Dr. Itzchak Angel, Former Head of Pharmacology at Synthelabo (Now Sanofi-Aventis), to Lead IND and INAD Applications for Human and Veterinary IndicationsACCESS NewswireMIAMI, FL / ACCESSWIRE / September 4, 2024 / Telomir Pharmaceuticals, Inc. , a pre-clinical-stage company seeking to lead developments in longevity science
2y agoTELOTelomir Pharmaceuticals Featured in Local ABC Exclusive Showing Positive Outcomes of Proposed Age Reversal Pill in DogsACCESS NewswirePromising results with Telomir-1 Demonstrates Potential in Promoting Life Quality and Longevity in Senior DogsTAMPA, FL / ACCESSWIRE / August 20, 2024 / Telomir Pharmaceuticals, Inc. ("Telomir" or
2y agoMIRA TELOTelomir Pharmaceuticals Mourns the Passing of Chairman and CEO Dr. Christopher ChapmanGlobeNewswireTelomir Board of Directors appoints Erez Aminov as CEO and Chairman of the Board Telomir also announces Board of Directors departures and additions TAMPA, Fla., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Telomir
2y agoTELOTelomir Pharmaceuticals Added to Membership of Russell 3000 and Russell Microcap IndexesGlobeNewswireTAMPA, Fla., July 02, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of
2y agoTELOTelomir Pharmaceuticals Scientific Advisor to Participate in Drug Information Association 2024 Global Annual Meeting PanelGlobeNewswireTAMPA, Fla., June 17, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of
2y agoTELOTelomir Pharmaceuticals Announces Two Pivotal Milestones for Lead Product Candidate Telomir-1GlobeNewswireCommences the study, The Safety of Telomir-1 when Administered Orally to Geriatric Laboratory Beagle Dogs for 63 Consecutive Days study to evaluate the safety of Telomir-1 on geriatric canines Began geriatric canine
2y agoLRHC TELONew to The Street TV Announces Episode 575 with its Four Business Guest Interviews, Airs as Sponsored Programming on Bloomberg TV, Saturday, May 25, 2024, at 6:30 PM ETGlobeNewswireNEW YORK, May 24, 2024 (GLOBE NEWSWIRE) -- FMW Media's New to The Street announces broadcasting of its national business show that will air as a sponsored program on Bloomberg TV on Saturday, May 25, 2024, at 6:30